OncRef

Clinical Trial: NCT02402920

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:M.D. Anderson Cancer Center
Information Provided By:M.D. Anderson Cancer Center
Last Update Posted:2026-03-10

Study Overview

Brief Summary

This phase I trial studies the side effects and best dose of pembrolizumab when given together with chemoradiotherapy or radiation therapy in treating patients with small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more cancer cells. Giving pembrolizumab with chemoradiotherapy or radiation therapy may be a better treatment for small cell lung cancer.

Official Title

Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer

Conditions

Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm

Intervention / Treatment

  • Drug: Carboplatin
  • Drug: Cisplatin
  • Drug: Etoposide
  • Other: Laboratory Biomarker Analysis
  • Biological: Pembrolizumab
  • Procedure: Radiation Therapy

Other Study ID Numbers

  • 2014-1003
  • NCI-2015-00598
  • 2014-1003
  • P30CA016672

Start Date (Actual)

2015-07-22

Primary Completion Date (Actual)

2025-12-23

Study Completion Date (Actual)

2026-02-09

Enrollment (Actual)

83

Study Type

Interventional

Phase

Phase 1